Edition:
United Kingdom

Jiangsu Hengrui Medicine Co Ltd (600276.SS)

600276.SS on Shanghai Stock Exchange

94.68CNY
23 May 2018
Change (% chg)

¥-0.46 (-0.48%)
Prev Close
¥95.14
Open
¥94.81
Day's High
¥96.43
Day's Low
¥94.23
Volume
11,530,621
Avg. Vol
12,510,382
52-wk High
¥96.43
52-wk Low
¥48.35

Chart for

About

JIANSU HENGRUI MEDICINE CO., LTD. is a China-based company, principally engaged in the manufacture and distribution of pharmaceutical tablets, injections and raw materials. The Company's main products portfolio consists of antineoplastic drugs, angiomyocardiac drugs, drugs for surgery, contrast agents, antibiotics, specialty... (more)

Overall

Beta: 0.50
Market Cap(Mil.): ¥168,815.80
Shares Outstanding(Mil.): 2,816.88
Dividend: 0.11
Yield (%): 0.19

Financials

  600276.SS Industry Sector
P/E (TTM): 59.17 30.95 32.75
EPS (TTM): 1.01 -- --
ROI: 23.31 14.84 14.38
ROE: 23.04 16.34 16.07

BRIEF-Jiangsu Hengrui Medicine unit passes U.S. FDA approval

* Says co's unit Shanghai Hengrui Pharmaceutical Co Ltd received FDA approval for desflurane for inhalation (product) from U.S. Food and Drug Administration

02 Mar 2018

BRIEF-Jiangsu Hengrui Medicine receives GMP certificate

* Says it received goods manufacture practice (GMP) certificate from Health and Youth Care Inspectorate

28 Feb 2018

BRIEF-TG Therapeutics, Jiangsu Hengrui Announce Agreement For BTK Inhibitor Program For Treatment Of Hematologic Malignancies

* TG THERAPEUTICS AND JIANGSU HENGRUI MEDICINE ANNOUNCE GLOBAL LICENSE AGREEMENT FOR DEVELOPMENT AND COMMERCIALIZATION OF NOVEL BTK INHIBITOR PROGRAM FOR THE TREATMENT OF HEMATOLOGIC MALIGNANCIES

08 Jan 2018

BRIEF-Jiangsu Hengrui Medicine passes U.S. FDA approval

* Says it received FDA approval for Dexmedetomidine Hydrochloride Injection from U.S. Food and Drug Administration

29 Nov 2017

Earnings vs. Estimates